These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33488383)

  • 1. Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease.
    Aksnes M; Tiiman A; Edwin TH; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
    Front Aging Neurosci; 2020; 12():608628. PubMed ID: 33488383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer's Disease in a Memory Clinic Cohort.
    Aksnes M; Müller EG; Tiiman A; Edwin TH; Terenius L; Revheim ME; Vukojević V; Bogdanović N; Knapskog AB
    J Alzheimers Dis; 2020; 77(2):831-842. PubMed ID: 32741818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.
    Aksnes M; Aass HCD; Tiiman A; Edwin TH; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
    Transl Neurodegener; 2021 Jun; 10(1):18. PubMed ID: 34099032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimer's Disease: Pilot Study in a Small Naturalistic Memory Clinic Cohort.
    Aksnes M; Aass HCD; Tiiman A; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
    J Alzheimers Dis; 2022; 86(3):1459-1470. PubMed ID: 35213378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42.
    Lauridsen C; Sando SB; Møller I; Berge G; Pomary PK; Grøntvedt GR; Salvesen Ø; Bråthen G; White LR
    Front Aging Neurosci; 2017; 9():210. PubMed ID: 28701950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis.
    Tiiman A; Jelić V; Jarvet J; Järemo P; Bogdanović N; Rigler R; Terenius L; Gräslund A; Vukojević V
    J Alzheimers Dis; 2019; 68(2):571-582. PubMed ID: 30814355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of PTHrP levels in CSF with Alzheimer's disease biomarkers.
    Kushnir MM; Michno W; Rockwood AL; Blennow K; Strathmann FG; Hanrieder J
    Clin Mass Spectrom; 2019 Nov; 14 Pt B():124-129. PubMed ID: 34917769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.
    Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR
    Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
    Travassos M; Santana I; Baldeiras I; Tsolaki M; Gkatzima O; Sermin G; Yener GG; Simonsen A; Hasselbalch SG; Kapaki E; Mara B; Cunha RA; Agostinho P; Blennow K; Zetterberg H; Mendes VM; Manadas B; de Mendon A
    J Alzheimers Dis; 2015; 47(4):1069-78. PubMed ID: 26401784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.
    Hansson O; Lehmann S; Otto M; Zetterberg H; Lewczuk P
    Alzheimers Res Ther; 2019 Apr; 11(1):34. PubMed ID: 31010420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.